Areas of Expertise:
Hematologic malignancies, Blood and marrow transplantation, Immunotherapy, Immune function in children with cancer, Extracorporeal photopheresis
Locations: Main Campus
Education and Training
MD - Virginia Commonwealth University, Richmond, VA
Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA
Pediatric Hematology and Oncology - The Children's Hospital of Philadelphia, PA
PhD in Human Genetics - Virginia Commonwealth University, Richmond, VA
Titles and Academic Titles
Assistant Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Departments and Services
Areas of Focus
- Chimeric Antigen Receptor T-cell Therapy for Neuroblastoma
- Predicting and Managing Cytokine Release Syndrome in CART-19 Therapy
- Modified CAR T-Cell Therapy in the Treatment of Refractory and Relapsed Neuroblastoma
Laboratories & Research Programs
Bagashev A, Sotillo E, Tang CA, Black KL, Perazzelli J, Seeholzer SH, Argon Y, Barrett DM, Grupp SA, Hu CA, Thomas-Tikhonenko A. CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. Mol Cell Biol. 2018 Aug 13. pii: MCB.00383-18. doi: 10.1128/MCB.00383-18. [Epub ahead of print]
Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.
Singh N, Hofmann TJ, Gershenson Z, Levine BL, Grupp SA, Teachey DT, Barrett DM. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy. 2017 Jul;19(7):867-880. doi: 10.1016/j.jcyt.2017.04.001. Epub 2017 May 11.
Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit Care Med. 2017 Feb;45(2):e124-e131. doi: 10.1097/CCM.0000000000002053. PMID: 27632680
Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016 Oct 3;126(10):3814-3826. doi: 10.1172/JCI87366. Epub 2016 Aug 29. PMID: 27571406
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016 Apr 13. pii: CD-16-0040. [Epub ahead of print]
Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016 Mar 3;127(9):1117-27.
Singh N, Perazzelli J, Grupp SA and Barrett DM: Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Science Translational Medicine. 8(320):320ra3, Jan 2016.
Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A.: Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discovery. 5(12):1282-95, Dec 2015.
Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, Negri GL, Lin Y, Zou J, Mallon BS, Maude S, Teachey DT, Barrett DM, Orentas RJ, Daugaard M, Sorensen PH, Grupp SA, Fry TJ.: Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood 126(5): 629-39, July 2015.
Wang E, Wang LC, Tsai CY, Bhoj V, Gershenson Z, Moon EK, Newick K, Sun J, Lo A, Baradet T, Feldman M, Barrett DM, Pure E, Albelda SM, Milone MC: Generation of Potent T cell Immunotherapy for Cancer using DAP12-based, Multichain, Chimeric Immunoreceptors. Cancer Immunol Res. 3(7): 815-26, May 2015.
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA.: Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine 371(16): 1507-17, October 2014.
T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. Oncoimmunology. 2015 Aug 12;5(1):e1040216. Singh N, Kulikovskaya I, Barrett DM, Binder-Scholl G, Jakobsen B, Martinez D, Pawel B, June CH, Kalos MD, Grupp SA.
Singh N, Liu X, Hulitt J, Jiang S, June CH, Grupp SA, Barrett DM*, Zhao Y*.: Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunology Research 2(11): 1059-70, August 2014.
Bassiri H, Das R, Guan P, Barrett DM, Brennan PJ, Banerjee PP, Wiener SJ, Orange JS, Brenner MB, Grupp SA, Nichols KE: iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo. Cancer Immunology Research 2(1): 59-69, January 2014.
Barrett DM, Singh N, Liu X, Jiang S, June CH, Grupp SA, Zhao Y: Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy 16(5): 619-30, January 2014.
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, Grupp SA. Blood. 2013 Jun 27;121(26):5154-7.
Ruella M*, Barrett DM*, Kenderian SA, Shestova O, Hofmann TJ, Scholler J, Lacey S, Melenhorst J, Nazimuddin F, Perazzelli J, Christian D, Hunter C, Porter DL, June CH, Grupp SA, and Gill S. : Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies. American Society of Hematology Annual Meeting December 2015.
Grupp SA, Maude S, Shaw P, Aplenc R, Barrett DM, Callahan C, Lacey S, Levine BL, Melenhorst J, Motley L, Rheingold S, Teachey DT, Wood PA, Porter D, June CH: Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-targeted Chimeric Antigen Receptor (CTL019) American Society of Hematology Annual Meeting December 2015.
Sotillo E, Barrett DM, Bagashev A, Black K, Lanauze C, Oldridge D, Sussman R, Harrington C, Chung EY, Hofmann TJ, Maude SL, Martinez NM, Raman P, Ruella M, Allman D, Jacoby E, Fry T, Barash Y, Lynch K, Mackall C, Maris JM, Grupp SA, Thomas-Tikhonenko A: Alternative splicing of CD19 mRNA in leukemias escaping CART-19 immunotherapy eliminates the cognate epitope and contributes to treatment failure American Association for Cancer Research Annual Meeting April 2015.
Singh N, Perazzelli JH, Grupp SA and Barrett DM : Fitness of T cells for adoptive immunotherapy for pediatric malignancies. American Association for Cancer Research Annual Meeting April 2015.
Seif AE, Jo S, Altman J, Bassiri H, Barrett DM, Grupp SA, and Reid GSD: Epitope spreading is required for long-term protection against acute lymphoblastic leukemia. American Society of Hematology Annual Meeting December 2014.
Ruella M, Barrett DM, Grupp SA and Gill S.: Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies. American Society of Hematology Annual Meeting December 2014.
Barrett DM, Singh N, Levine BL, June CH and Grupp SA.: The monocyte lineage is required for production of clinically relevant interleukin-6 (IL-6) during chimeric antigen receptor (CAR) T cell based killing of leukemia. American Association for Cancer Research Annual Meeting May 2014.
Ruella M, Shestova O, Kenderian S, Barrett DM, Grupp SA, Scholler J,Lacey S, Kalos M, June CH, and Gill S.: ANTI-CD123 Chimeric Antigen Receptor Redirected T Cells For Relapsed B-Cell Acute Lymphoblastic Leukemia. International Society for Cellular Therapy Annual Meeting 16(4S), April 2014.
Posters and Presentations
Barrett DM. Chimeric Antigen Receptor Therapy for Pediatric Malignancies [invited lecture]. Virginia Commonwealth University; 2016 Feb; Richmond, VA.
Barrett DM. Chimeric Antigen Receptor Therapy for Pediatric Cancer [invited lecture]. University of Texas Southwestern; 2016 Jan; Dallas, TX.
Barrett DM. Chimeric Antigen Receptor Therapy for Pediatric Leukemia [invited lecture]. Association of Molecular Pathology; 2015 Nov; Austin, TX.
Barrett DM. Chimeric Antigen Receptor Biology [invited lecture]. Children's Oncology Group; 2015 Oct; Dallas, TX.
Barrett DM. T cells in pediatric ALL: Biology versus Therapy [invited lecture]. Children’s Oncology Group; 2015 Oct; Dallas, TX.
Barrett DM. CD19 Targeted Chimeric Antigen Receptor Therapy for ALL [invited lecture]. Symposium zur 3000 Transplantation in Leipzig; 2015 Jul; Leipzig, Germany.
Barrett DM. Cellular Therapy for Childhood Cancer [invited lecture]. Nationwide Children's Hospital Oncology Seminar Series; 2015 Apr 15; Columbus, OH.
Barrett DM. Durable Remissions in Pediatric Leukemia Using CD19 Chimeric Antigen Receptor T cells [invited lecture]. American Society of Hematology; 2014 Dec; San Francisco, CA.
Barrett DM. Insights into Cytokine Release Syndrome from Patient Derived Xenograft Models of Pediatric Leukemia for Adoptive Immunotherapy [invited lecture]. American Society for Gene and Cell Therapy; 2014 May; Washington, DC.
Barrett DM. Chimeric Antigen Receptor Therapy for Cancer [invited lecture]. Division of Oncology Grand Rounds, Rainbow Babies Children's Hospital; 2014 May; Cleveland, OH.
Awards and Honors
2015, Award in Basic Research, Immuno-oncology Young Investigator Forum
2012, St. Baldrick's Foundation Scholar
2011, American Society of Pediatric Hematology and Oncology Young Investigator Award
2010, Travel Stipend Award / American Society of Pediatric Hematology/Oncology
2010, Scholar in Training Award / American Association for Cancer Research
2009, Presidential Travel Award / International Society for the Biological Therapy of Cancer
2004, Phi Kappa Phi Honor Society
2003, Roscoe D. Hughes Award for Outstanding Research in Human Genetics / Virginia Commonwealth University
1999, Alpha Omega Alpha Honor Medical Society
Editorial and Academic Positions
2011-present, Ad Hoc reviewer Biology of Blood and Marrow Transplant, Blood
Academic and Institutional Committees
2013-present, Pediatric Protocol Review Committee, Reviewer with focus on Blood and Marrow Transplant
Leadership and Memberships
Memberships in Professional Organizations
2009, present International Society for the Biological Therapy of Cancer
2004-present, American Academy of Pediatrics
2004-present, American Medical Society
2008-present, American Association for Cancer Research
2008-present, American Society of Pediatric Hematology and Oncology
Patient Experience Ratings
About the Patient Experience Rating System
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.